Skip to playerSkip to main content
  • 6 weeks ago
Eli Lilly's newly launched obesity pill Foundayo recorded 1,390 U.S. prescriptions in the week ended April 10, following its April 1st approval. Novo Nordisk's oral Wegovy reached 113,354 prescriptions in the same week, up from 105,366 the prior week. Guggenheim analysts noted Lilly expects early prescription data volatility. Eli Lilly shares rose nearly 3% in premarket trading.
Transcript
00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Eli Lilly's newly launched obesity pill recorded 1,390 U.S. prescriptions in the week,
00:08ended April 10th, according to Reuters.
00:11Novo Nordisk's Oral Wegevy reached 3,071 prescriptions in its first four days after
00:17its January 5th launch and totaled 113,354 prescriptions in the same week, up from 105,366
00:26the prior week.
00:29Fondeo received approval on April 1st, with prescriptions accepted immediately and shipping
00:33starting April 6th, followed by broader U.S. availability on April 9th.
00:38Guggenheim analysts said Lilly expects volatility in early prescription data due to varying capture
00:43rates.
00:44Shares of Eli Lilly rose nearly 3% in pre-market trading.
00:48The company did not immediately respond to Reuters' request for comment.
00:52For all things money, visit Benzinga.com.
Comments

Recommended